Tags: Neuroimaging
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
blog
January 30, 2018
Meeting the Challenge of CTE
For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease.
blog
December 28, 2017
Alzheimer’s Biomarkers, Explained
Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.
announcements
September 27, 2016
Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain
Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death
announcements
July 7, 2016
Five New Grants Fund Promising Treatments & Biomarkers
The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.
announcements
May 10, 2016
Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
blog
July 28, 2014
5 Highlights from the Largest Alzheimer’s Conference
Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.
blog
May 20, 2014
The Case for Dementia Screening
Healthcare professionals rarely screen patients—even those with many risk factors—for cognitive issues or dementia.
blog
August 19, 2013
The Balancing Act of Healthcare Reform
I recently saw a patient who was afraid he had Alzheimer's disease. A new scan made it easy to give him an accurate diagnosis. So why can't most patients use it?
announcements
February 5, 2013
Medicare Panel’s Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans
Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.
announcements
April 6, 2012
ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease
The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024